Essilor Stellest Lens Gains FDA Market Authorization, Will Be Available in U.S. in Coming Weeks

PARIS—EssilorLuxottica announced today that the U.S. Food and Drug Administration (FDA) has granted market authorization for its Essilor Stellest lens, making it the first FDA market-authorized spectacle lens proven to slow myopia progression in children. The effectiveness of the Essilor Stellest lens has been demonstrated by clinical data, which shows that the lens slowed down myopia progression by 71 percent on average over two years, the company noted, citing both a prospective, randomized, multicenter U.S. clinical trial as well as data on file. Previously launched in key countries worldwide, the Essilor Stellest lens will be available for U.S. eyecare professionals to equip children in coming weeks, the company advised.